A double-blind randomized placebo-controlled trial of XXXX for the treatment of @entity1561 .

@entity1 @entity350 @entity82 @entity1560 @entity2690 @entity1561 @entity493 @entity413
BACKGROUND _ AIMS: Few controlled studies have addressed the issue of effective medical treatment for @entity1561 ( @entity1561 ). We herein assessed the effect of @entity350 in @entity1 with @entity1561 . METHODS: We performed a randomized, double-blind, placebo-controlled study on 52 @entity1 with @entity1561 diagnosed by ultrasound (US) and confirmed by liver biopsy (40 @entity1 ). The @entity1 were randomized to receive either @entity350 (120 mg 3 times daily for 6 months) or placebo. All @entity1 participated in an identical behavioral weight loss program. All @entity1 underwent monthly evaluation by abdominal US; liver enzyme levels, lipid profiles, @entity2690 levels, and anthropometric parameters were monitored, and all @entity1 underwent nutritional follow-up evaluation. Twenty-two @entity1 underwent a second liver biopsy examination at the end of the study. RESULTS: Fifty-two @entity1 were recruited and 44 (mean age, 47.7 y; mean body mass index, 33) completed the study. Serum @entity413 and @entity2690 levels (P<.03) were significantly higher in the @entity350 group, which also presented a higher degree of @entity82 . Body mass index was reduced significantly in each group, with a nonsignificant difference between the groups. Serum @entity493 transaminase (ALT) levels decreased significantly in both groups, with an almost 2-fold reduction in the @entity350 group (48% vs 26.4%). There was a statistically significant @entity1560 by US only in the @entity350 group (P<.05). CONCLUSIONS: @entity350 improves serum ALT levels and @entity1560 on US in @entity1561 @entity1 , beyond its effect on weight reduction.
